Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Radiogenomics in lung cancer: Where are we?

  • Aguado-Barrera, Miguel E.
  • Sosa-Fajardo, Paloma
  • Gómez-Caamaño, Antonio
  • Taboada-Valladares, Begoña
  • Couñago, Felipe
  • López-Guerra, José Luis
  • Vega, Ana I.
Huge technological and biomedical advances have improved the survival and quality of life of lung cancer patients treated with radiotherapy. However, during treatment planning, a probability that the patient will experience adverse effects is assumed. Radiotoxicity is a complex entity that is largely dose-dependent but also has important intrinsic factors. One of the most studied is the genetic variants that may be associated with susceptibility to the development of adverse effects of radiotherapy. This review aims to present the current status of radiogenomics in lung cancer, integrating results obtained in association studies of SNPs (single nucleotide polymorphisms) related to radiotherapy toxicities. We conclude that despite numerous publications in this field, methodologies and endpoints vary greatly, making comparisons between studies difficult. Analyzing SNPs from the candidate gene approach, together with the study in cohorts limited by the sample size, has complicated the possibility of having validated results. All this delays the incorporation of genetic biomarkers in predictive models for clinical application. Thus, from all analysed SNPs, only 12 have great potential as esophagitis genetic risk factors and deserve further exploration. This review highlights the efforts that have been made to date in the radiogenomic study of radiotoxicity in lung cancer., Contract grant sponsor Ana Vega: supported by Spanish Instituto de Salud Carlos III (ISCIII) funding, an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds [INT20/00071; PI19/01424]; the Autonomous Government of Galicia, Consolidation and structuring program [IN607B]; the Fundación Mutua Madrileña [MMA2018-1, 2018]; and the Asociación Española Contra el Cáncer (AECC) [PRYES211091VEGA, 2021]., Peer reviewed